First Trust Advisors LP Trims Stake in Takeda Pharmaceutical Co. $TAK

First Trust Advisors LP cut its stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 5.6% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,601,808 shares of the company’s stock after selling 154,147 shares during the period. First Trust Advisors LP owned about 0.08% of Takeda Pharmaceutical worth $40,224,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. Twin Peaks Wealth Advisors LLC bought a new position in shares of Takeda Pharmaceutical in the second quarter worth about $28,000. Evelyn Partners Investment Management LLP grew its stake in shares of Takeda Pharmaceutical by 163.4% during the 2nd quarter. Evelyn Partners Investment Management LLP now owns 2,515 shares of the company’s stock valued at $39,000 after acquiring an additional 1,560 shares during the period. NewSquare Capital LLC increased its holdings in Takeda Pharmaceutical by 182.4% in the 2nd quarter. NewSquare Capital LLC now owns 3,451 shares of the company’s stock worth $53,000 after acquiring an additional 2,229 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in Takeda Pharmaceutical by 56.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock worth $55,000 after acquiring an additional 1,292 shares in the last quarter. Finally, MAI Capital Management raised its stake in Takeda Pharmaceutical by 212.4% during the 2nd quarter. MAI Capital Management now owns 5,177 shares of the company’s stock worth $80,000 after acquiring an additional 3,520 shares during the period. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

Shares of NYSE TAK opened at $14.26 on Wednesday. The company has a market cap of $45.36 billion, a P/E ratio of 178.19 and a beta of 0.03. Takeda Pharmaceutical Co. has a 52-week low of $12.80 and a 52-week high of $15.69. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.76 and a current ratio of 1.37. The firm’s fifty day moving average is $14.09 and its two-hundred day moving average is $14.62.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Thursday, October 30th. The company reported $0.44 EPS for the quarter, meeting the consensus estimate of $0.44. Takeda Pharmaceutical had a net margin of 0.86% and a return on equity of 10.32%. The business had revenue of $7.30 billion during the quarter, compared to the consensus estimate of $8.01 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. As a group, analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on TAK. Zacks Research lowered shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Thursday, August 21st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Takeda Pharmaceutical in a report on Monday, December 1st. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold”.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.